SCHEMBL5163607

SCHEMBL5163607

O=C(CC(=O)N1CCCCC1)c1ccsc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
HDAC1 Q13547 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
DAO P14920 1/20 0.42
HTR1A P08908 2/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
HSD11B1 P28845 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158833 0.98 CES2 (0.44) CES2CES1HDAC1LCKFYN
SCHEMBL12181436 0.79 NPC1 (0.53) HDAC1ALDH1A1NPC1SMN1; SMN2
SCHEMBL22721318 0.77 CES1 (0.62) CES2CES1HDAC1LCKFYN
SCHEMBL6692694 0.77 HPGD (0.59) CES1ALDH1A1HPGDKMT2APOLB
SCHEMBL10682436 0.76 HPGD (0.59) CES2CES1LCKFYNDAO
SCHEMBL5160900 0.74 PLOD2 (0.51) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL5158586 0.72 PLOD2 (0.53) ALDH1A1HPGDRAB9ASMN1; SMN2CYP1A2
SCHEMBL4336119 0.72 LCK (0.59) CES2CES1HDAC1LCKFYN
SCHEMBL5161345 0.72 TRPA1 (0.43) ALDH1A1HPGDRXFP1RAB9ANPC1
SCHEMBL5160787 0.72 HPGD (0.41) ALDH1A1HPGDKMT2APOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CES2 441/4885CES1 382/4885HDAC1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.